The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FEMY | -42.98% | N/A | N/A | -95% |
| S&P | +13.59% | +79.97% | +12.46% | +66% |
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $729.39K | 31.4% |
| Gross Profit | $224.48K | 51.3% |
| Gross Margin | 30.78% | 4.0% |
| Market Cap | $15.16M | -38.6% |
| Market Cap / Employee | $213.47K | 0.0% |
| Employees | 71 | 0.0% |
| Net Income | -$4,194.82K | 22.4% |
| EBITDA | -$3,442.69K | 29.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.57M | -40.0% |
| Accounts Receivable | $572.20K | 51.3% |
| Inventory | 5.8 | 198.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.15M | -82.9% |
| Short Term Debt | $7.28M | 1284.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -124.24% | -5.3% |
| Return On Invested Capital | -161.17% | -78.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5,581.71K | 5.1% |
| Operating Free Cash Flow | -$5,387.38K | 1.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.10 | 12.67 | 13.10 | 7.61 | 84.20% |
| Price to Sales | 15.39 | 18.50 | 14.78 | 7.01 | -64.18% |
| Price to Tangible Book Value | 4.15 | 13.04 | 13.50 | 7.91 | 89.03% |
| Enterprise Value to EBITDA | -6.45 | -6.73 | -8.94 | -5.32 | 7.29% |
| Return on Equity | -182.2% | -239.9% | -329.5% | -376.2% | 70.56% |
| Total Debt | $7.44M | $7.67M | $7.85M | $8.43M | 16.44% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
